

Pia Raanani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2381872/publications.pdf>

Version: 2024-02-01

226
papers

4,010
citations

136740

32
h-index

161609

54
g-index

231
all docs

231
docs citations

231
times ranked

5734
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunoglobulin Prophylaxis in Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2009, 27, 770-781.	0.8	140
2	Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. <i>Haematologica</i> , 2016, 101, 1065-1073.	1.7	130
3	Immune-Mediated Complications during Interferon Therapy in Hematological Patients. <i>Acta Haematologica</i> , 2002, 107, 133-144.	0.7	127
4	Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2009, 50, 764-772.	0.6	125
5	Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatricâ€inspired regimens: Systematic review and metaâ€analysis. <i>American Journal of Hematology</i> , 2012, 87, 472-478.	2.0	118
6	Cell-specific uptake of mantle cell lymphoma-derived exosomes by malignant and non-malignant B-lymphocytes. <i>Cancer Letters</i> , 2015, 364, 59-69.	3.2	117
7	The late adverse events of rituximab therapy â€ rare but there!. <i>Leukemia and Lymphoma</i> , 2009, 50, 1083-1095.	0.6	116
8	Lymphoma and Leukemia Cells Possess Fractal Dimensions That Correlate with Their Biological Features. <i>Acta Haematologica</i> , 2008, 119, 142-150.	0.7	104
9	5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis. <i>Haematologica</i> , 2010, 95, 303-310.	1.7	92
10	MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCRâ€ABL protein. <i>Cancer Letters</i> , 2015, 356, 597-605.	3.2	75
11	Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. <i>Haematologica</i> , 2009, 94, 712-719.	1.7	74
12	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 122, 457-464.	1.2	73
13	Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E16-22.	3.3	73
14	The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1997, 99, 945-950.	1.2	72
15	Challenges in Oncology. <i>Journal of Clinical Oncology</i> , 2002, 20, 869-870.	0.8	72
16	Management of adult patients with acute lymphoblastic leukemia in first complete remission. <i>Cancer</i> , 2010, 116, 3447-3457.	2.0	70
17	Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 2001, 42, 683-687.	0.6	62
18	Philadelphia-Chromosome-Positive T-Lymphoblastic Leukemia: Acute Leukemia or Chronic Myelogenous Leukemia Blastic Crisis. <i>Acta Haematologica</i> , 2005, 113, 181-189.	0.7	62

#	ARTICLE	IF	CITATIONS
19	Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. <i>The Cochrane Library</i> , 2024, 2024, CD006501.	1.5	62
20	Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of Aa Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1770-1775.	2.0	61
21	Primary analysis of JUMP, a phase 3b, expanded access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020, 189, 888-903.	1.2	61
22	Rituximab-associated acute thrombocytopenia: An underdiagnosed phenomenon. <i>American Journal of Hematology</i> , 2009, 84, 247-250.	2.0	59
23	Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study. <i>Annals of Hematology</i> , 2019, 98, 1927-1932.	0.8	56
24	Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. <i>Cancer Letters</i> , 2015, 360, 245-256.	3.2	55
25	Diffuse Alveolar Hemorrhage in Acute Promyelocytic Leukemia Patients Treated with ATRA - A Manifestation of the Basic Disease or the Treatment. <i>Leukemia and Lymphoma</i> , 2000, 37, 605-610.	0.6	53
26	Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies. <i>Haematologica</i> , 2022, 107, 715-720.	1.7	51
27	Renal failure associated with tyrosine kinase inhibitors—Case report and review of the literature. <i>Leukemia Research</i> , 2010, 34, 123-127.	0.4	48
28	The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. <i>American Journal of Medicine</i> , 2017, 130, 826-832.	0.6	48
29	Ponatinib reduces viability, migration, and functionality of human endothelial cells. <i>Leukemia and Lymphoma</i> , 2017, 58, 1455-1467.	0.6	46
30	An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2022, 139, 1098-1110.	0.6	46
31	Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 189-199.	0.6	43
32	Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. <i>Thrombosis Research</i> , 2018, 166, 106-112.	0.8	39
33	Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. <i>Cardio-Oncology</i> , 2015, 1, 5.	0.8	38
34	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 937-944.	2.0	37
35	Thrombotic Thrombocytopenic Purpura Complicating Chronic Myelogenous Leukemia Treated with Interferon- α . <i>Acta Haematologica</i> , 1998, 100, 204-206.	0.7	34
36	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	1.9	34

#	ARTICLE	IF	CITATIONS
37	Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. <i>Oncogene</i> , 2003, 22, 7649-7660.	2.6	33
38	Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016, 172, 89-96.	1.2	33
39	Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia. <i>Cancer Letters</i> , 2003, 199, 185-192.	3.2	32
40	Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis. <i>Haematologica</i> , 2013, 98, 95-102.	1.7	31
41	Cardiovascular calcifications after radiation therapy for Hodgkin lymphoma: computed tomography detection and clinical correlation. <i>Coronary Artery Disease</i> , 2006, 17, 145-151.	0.3	30
42	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.	2.5	28
43	Acute Neutrophilic Dermatitis Induced by All-Trans-Retinoic Acid Treatment for Acute Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 34, 401-404.	0.6	25
44	Hypertension in cancer patients treated with anti-angiogenic based regimens. <i>Cardio-Oncology</i> , 2015, 1, 6.	0.8	25
45	Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. <i>Leukemia and Lymphoma</i> , 2016, 57, 63-69.	0.6	25
46	FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. <i>Hematological Oncology</i> , 2019, 37, 168-175.	0.8	25
47	COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 3384-3393.	0.6	25
48	ATG plus Cyclosporine Reduces All-Cause Mortality in Patients with Severe Aplastic Anemia â€” Systematic Review and Meta-Analysis. <i>Acta Haematologica</i> , 2008, 120, 237-243.	0.7	24
49	High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patientsâ€”Systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2011, 86, 657-662.	2.0	24
50	Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. <i>Hematological Oncology</i> , 2020, 38, 584-588.	0.8	24
51	Assessment of the response to imatinib in chronic myeloid leukemia patients - comparison between the FISH, multiplex and RT-PCR methods. <i>European Journal of Haematology</i> , 2004, 73, 243-250.	1.1	23
52	cDNA Microarray Analysis Reveals an Overexpression of the Dual-Specificity MAPK Phosphatase PYST2 in Acute Leukemia. <i>Methods in Enzymology</i> , 2003, 366, 103-113.	0.4	21
53	Bendamustine-associated infectionsâ€”systematic review and meta-analysis of randomized controlled trials. <i>Hematological Oncology</i> , 2017, 35, 424-431.	0.8	21
54	Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e295-e301.	0.2	21

#	ARTICLE	IF	CITATIONS
55	Gelatinous Transformation of Bone Marrow in Chronic Myeloid Leukemia during Treatment with Imatinib Mesylate: A Disease or a Drug Effect?. <i>Acta Haematologica</i> , 2008, 119, 104-107.	0.7	20
56	Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL ⁺) cells sensitive and resistant to imatinib. <i>Experimental Hematology</i> , 2010, 38, 27-37.	0.2	20
57	The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. <i>Leukemia Research</i> , 2013, 37, 1057-1062.	0.4	20
58	Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 123-126.	1.1	19
59	Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. <i>Leukemia and Lymphoma</i> , 2021, 62, 918-926.	0.6	19
60	BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon- γ . <i>British Journal of Haematology</i> , 1998, 102, 1271-1278.	1.2	18
61	Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) – a systematic review and meta-analysis of randomized trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2047-2057.	0.6	18
62	Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. <i>Hematological Oncology</i> , 2019, 37, 569-577.	0.8	17
63	Obinutuzumab-related adverse events: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021, 39, 215-221.	0.8	17
64	Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized haemato-oncological patients: Randomized controlled trial. <i>American Journal of Hematology</i> , 2014, 89, 243-248.	2.0	16
65	Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34 ⁺ CD38 ⁺ cells through iron chelation, induction of ROS, and inhibition of HIF1 α expression. <i>Experimental Hematology</i> , 2019, 70, 55-69.e4.	0.2	16
66	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. <i>Pharmaceutics</i> , 2020, 12, 520.	2.0	16
67	Myeloma in Scar Tissue - An Underreported Phenomenon or an Emerging Entity in the Novel Agents' Era? A Single Center Series. <i>Acta Haematologica</i> , 2014, 132, 39-44.	0.7	15
68	Risk factors for mortality due to <i>Acinetobacter baumannii</i> bacteremia in patients with hematological malignancies – a retrospective study. <i>Leukemia and Lymphoma</i> , 2019, 60, 2787-2792.	0.6	15
69	Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. <i>Clinical Microbiology and Infection</i> , 2022, 28, 303.e1-303.e4.	2.8	15
70	Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells. <i>Cancer Letters</i> , 2012, 323, 223-231.	3.2	14
71	Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. <i>International Journal of Hematology</i> , 2019, 109, 553-562.	0.7	14
72	Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021, 60, 1335-1341.	0.8	14

#	ARTICLE	IF	CITATIONS
73	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. <i>Annals of Hematology</i> , 2022, 101, 379-387.	0.8	14
74	Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. <i>Leukemia Research</i> , 1999, 23, 695-700.	0.4	13
75	Acute Myeloid Leukemia Associated with Nephrotic Syndrome: Case Report and Literature Review. <i>Leukemia and Lymphoma</i> , 2002, 43, 1133-1136.	0.6	13
76	Burkitt's Lymphoma of the Ovary: Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2013, 129, 169-174.	0.7	13
77	Adherence-Related Issues in Adolescents and Young Adults with Hematological Disorders. <i>Acta Haematologica</i> , 2014, 132, 348-362.	0.7	13
78	MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 86020-86030.	0.8	13
79	Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e449-e461.	0.2	13
80	Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study. <i>Annals of Hematology</i> , 2019, 98, 2711-2717.	0.8	13
81	Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. <i>Cancer Genetics</i> , 2015, 208, 575-579.	0.2	12
82	High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia-is more better or more of the same?. <i>Hematological Oncology</i> , 2016, 34, 28-35.	0.8	12
83	First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response—a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2016, 55, 1077-1083.	0.8	11
84	Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 121-128.	1.0	11
85	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low, intermediate1, intermediate2, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. <i>Hematological Oncology</i> , 2021, 39, 558-566.	0.8	11
86	SEVERE HYPOPHOSPHATAEMIA IN AUTOGRAFT RECIPIENTS DURING ACCELERATED LEUCOCYTE RECOVERY. <i>British Journal of Haematology</i> , 1995, 91, 1031-1033.	1.2	10
87	Methimazole slows hepatocyte streaming in rats. <i>Digestive Diseases and Sciences</i> , 1997, 42, 1433-1437.	1.1	10
88	Apaf1 in Chronic Myelogenous Leukemia (CML) Progression: Reduced Apaf1 Expression is Correlated with a H179R p53 Mutation During Clinical Blast Crisis. <i>Cell Cycle</i> , 2007, 6, 589-594.	1.3	10
89	First line and salvage therapy with total therapy 3-based treatment for multiple myeloma—An extended single center experience. <i>Leukemia Research</i> , 2014, 38, 1401-1406.	0.4	10
90	PET-adapted therapy for advanced Hodgkin lymphoma—a systematic review. <i>Acta Oncologica</i> , 2018, 57, 765-772.	0.8	10

#	ARTICLE	IF	CITATIONS
91	The effect of R-CHOP dose reduction on overall survival of elderly patients with DLBCL â€“ comparative study. <i>Leukemia and Lymphoma</i> , 2018, 59, 904-910.	0.6	10
92	The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 27-34.	0.8	10
93	Management of Adult Patients with Acute Lymphoblastic Leukemia in First Complete Remission: Systematic Review and Meta-Analysis.. <i>Blood</i> , 2009, 114, 49-49.	0.6	10
94	Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 119.	1.7	10
95	Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling. <i>Leukemia Research</i> , 2013, 37, 956-962.	0.4	9
96	Screening for occult cancer in idiopathic venous thromboembolism â€” Systemic review and meta-analysis. <i>European Journal of Internal Medicine</i> , 2017, 42, 74-80.	1.0	9
97	Late onset neutropenia after rituximab and obinutuzumab treatment â€” characteristics of a class-effect toxicity. <i>Leukemia and Lymphoma</i> , 2021, 62, 2921-2927.	0.6	9
98	Azacitidine and Lenalidomide Combination In Higher-Risk Myelodysplastic Syndromes-Preliminary Results Of The Vilen-01 Protocol. <i>Blood</i> , 2013, 122, 1576-1576.	0.6	9
99	Follicular Lymphoma with Extensive Gastrointestinal Tract Involvement: Follow-up by Capsule Endoscopy. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1031-1035.	1.1	8
100	Management of Aplastic Anemia: The Role of Systematic Reviews and Meta-Analyses. <i>Acta Haematologica</i> , 2011, 125, 47-54.	0.7	8
101	High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2016, 135, 55-64.	0.7	8
102	Bone mineral density utilization in patients with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 703-710.	0.8	8
103	Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. <i>Acta Haematologica</i> , 2020, 143, 266-271.	0.7	8
104	Premature ageing following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1438-1446.	1.3	8
105	Profiling and bioinformatics analyses reveal chronic lymphocytic leukemia cells share a unique circular RNA expression pattern. <i>Experimental Hematology</i> , 2020, 85, 8-12.	0.2	8
106	Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen speciesâ€”and GSK3Î²â€”dependent mechanism. <i>British Journal of Haematology</i> , 2021, 192, 747-760.	1.2	8
107	R-CHOP compared to R-CHOPâ€”+â€”X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2021, 60, 744-749.	0.8	8
108	Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. <i>Leukemia Research</i> , 2016, 41, 56-61.	0.4	7

#	ARTICLE	IF	CITATIONS
109	Utility of PET-CT for Evaluation of Patients With Peripheral T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 687-691.	0.2	7
110	Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2922-2926.	0.6	7
111	Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e343-e348.	0.2	7
112	Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment. <i>European Journal of Internal Medicine</i> , 2020, 77, 86-96.	1.0	7
113	Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update. <i>Blood</i> , 2014, 124, 3197-3197.	0.6	7
114	Pathogenesis of Ponatinib Associated Vascular Disease in Chronic Myeloid Leukemia: An in Vitro Study. <i>Blood</i> , 2015, 126, 2798-2798.	0.6	7
115	Plasma Cell Dyscrasia with Polyneuropathy - POEMS Syndrome Presenting with Vasculitic Skin Lesions and Responding to Combination Chemotherapy. <i>Leukemia and Lymphoma</i> , 2000, 40, 209-213.	0.6	6
116	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	1.1	6
117	Spontaneous Regression of Hodgkin Lymphoma: Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2019, 141, 14-18.	0.7	6
118	Post-Liver Transplantation Anemia and Its Correlation with Mortality and Graft Failure. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3040-3051.	1.1	6
119	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. <i>Blood</i> , 2015, 126, 2799-2799.	0.6	6
120	Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine. <i>Platelets</i> , 2022, 33, 781-786.	1.1	6
121	Interferon β Modulates β -Galactoside β -2,6-Sialyltransferase Gene Expression in Rat Testes. <i>Biology of Reproduction</i> , 1995, 53, 1474-1477.	1.2	5
122	Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure. <i>Leukemia Research</i> , 2013, 37, 1729-1736.	0.4	5
123	Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?. <i>Cancer Letters</i> , 2014, 352, 21-27.	3.2	5
124	Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)â€”ViLen-01 protocol. <i>Annals of Hematology</i> , 2016, 95, 1811-1818.	0.8	5
125	Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. <i>Blood Advances</i> , 2020, 4, 3822-3828.	2.5	5
126	Alloimmunization and autoimmunization in adult transfusion-dependent thalassemia patients: a report from a comprehensive center in Israel. <i>Annals of Hematology</i> , 2020, 99, 2731-2736.	0.8	5

#	ARTICLE	IF	CITATIONS
127	Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2747-2754.	0.6	5
128	Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF). <i>Blood</i> , 2014, 124, 1859-1859.	0.6	5
129	Clinical and pathological predictors for FDG-PET/CT avidity in patients with marginal zone lymphoma—a retrospective cohort study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2290-2299.	3.3	5
130	Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome. <i>Israel Medical Association Journal</i> , 2016, 18, 433-434.	0.1	5
131	Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022, 11, 4156.	1.0	5
132	Total therapy-based treatment for multiple myeloma—a single center experience. <i>Annals of Hematology</i> , 2010, 89, 53-59.	0.8	4
133	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Leukemia: The Role of Meta-Analyses. <i>Acta Haematologica</i> , 2011, 125, 39-46.	0.7	4
134	Acute Promyelocytic Leukemia with a Smoldering Course Associated with Therapy-Related Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2011, 126, 152-156.	0.7	4
135	Hodgkin Lymphoma and Hypothermia: Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2014, 131, 227-230.	0.7	4
136	The association of central venous catheter placement timing with infection rates in patients with acute leukemia. <i>Leukemia Research</i> , 2015, 39, 311-313.	0.4	4
137	Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead. <i>Acta Haematologica</i> , 2016, 136, 43-44.	0.7	4
138	CHOP-like-14 compared to CHOP-like-21 for patients with aggressive lymphoma—a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , 2016, 55, 77-84.	0.8	4
139	Adult pre-B-cell acute lymphoblastic leukemia with unusually large proportion of bone marrow CD45 bright/high SS ^c blasts. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 161-164.	0.7	4
140	Intravenous immunoglobulin-induced acute thrombocytopenia. <i>Transfusion</i> , 2018, 58, 493-497.	0.8	4
141	Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e351-e362.	0.2	4
142	Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. <i>Acta Haematologica</i> , 2020, 143, 65-68.	0.7	4
143	Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3417.	1.0	4
144	Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 590-596.	1.0	4

#	ARTICLE	IF	CITATIONS
145	Diarrheal Morbidity During Hematopoietic Cell Transplantation: The Diagnostic Yield of Stool Cultures. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1023-1032.	1.8	4
146	Feasibility of CD24/CD11b as a Screening Test for Hematological Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 724.	1.1	4
147	Post-transplantation erythrocytosis in kidney transplant recipients: A retrospective cohort study. <i>European Journal of Haematology</i> , 2021, 107, 595-601.	1.1	4
148	Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence. <i>Blood</i> , 2015, 126, 1124-1124.	0.6	4
149	Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Blood</i> , 2016, 128, 1802-1802.	0.6	4
150	Molecular Mechanisms Involved in the Development of Extramedullary Disease Following the Administration of All-Trans Retinoic Acid to Patients with Acute Promyelocytic Leukemia. <i>Blood</i> , 2009, 114, 1596-1596.	0.6	4
151	Minimal Residual Disease in Hematological Malignancies. <i>Acta Haematologica</i> , 2004, 112, 5-7.	0.7	3
152	Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 685-691.	1.1	3
153	Treatment and prognosis of stage I follicular lymphoma in the modern era: does PET matter?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1163-1171.	0.6	3
154	Hypomethylating Agents-associated Infections: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 603-610.e1.	0.2	3
155	Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation: a single-center experience. <i>Leukemia and Lymphoma</i> , 2019, 60, 2230-2236.	0.6	3
156	Immune Mediated Cerebellar Ataxia: An Unknown Manifestation of Graft-versus-Host Disease. <i>Acta Haematologica</i> , 2019, 141, 19-22.	0.7	3
157	Managing Anti-Platelet Therapy in Thrombocytopenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment. <i>Thrombosis and Haemostasis</i> , 2019, 119, 163-174.	1.8	3
158	Dysfunctional endothelial progenitor cells in patients with Hodgkin's lymphoma in complete remission. <i>Cancer Medicine</i> , 2019, 8, 305-310.	1.3	3
159	Implementation of a Novel Protocol for Preventing Venous Thromboembolism in Otolaryngology Patients. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, 166, 297-304.	1.1	3
160	Rituximab Maintenance (MR) for Patients with Mantle Cell Lymphoma (MCL): a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). <i>Blood</i> , 2014, 124, 4466-4466.	0.6	3
161	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). <i>Blood</i> , 2016, 128, 3107-3107.	0.6	3
162	Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. <i>Annals of Hematology</i> , 2021, 100, 2879-2887.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 34-35.	0.6	3
164	Postremission therapy with two different dose regimens of cytarabine in adults with acute myelogenous leukemia. <i>Leukemia Research</i> , 1995, 19, 893-897.	0.4	2
165	The Use of Myeloid Colony-Stimulating Factors in Hematologic Malignancies: The Role of Systematic Reviews and Meta-Analyses. <i>Acta Haematologica</i> , 2011, 125, 68-79.	0.7	2
166	Agranulocytosis Associated with Waldenström Macroglobulinemia. <i>Acta Haematologica</i> , 2018, 140, 42-45.	0.7	2
167	Computed Tomography Findings Associated With 30-Day Mortality in Patients With Malignant Superior Vena Cava Syndrome. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 912-918.	0.5	2
168	Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. <i>Acta Haematologica</i> , 2020, 143, 73-77.	0.7	2
169	Genomic analysis of metastatic rhabdomyosarcoma masquerading as acute leukemia. <i>Pathology Research and Practice</i> , 2020, 216, 152779.	1.0	2
170	Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions. <i>Acta Haematologica</i> , 2020, 143, 446-451.	0.7	2
171	Epidural/spinal anesthesia during delivery in women with factor XI deficiency, a single center experience. <i>Haemophilia</i> , 2020, 26, 834-839.	1.0	2
172	Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration. <i>Leukemia and Lymphoma</i> , 2020, 61, 2216-2220.	0.6	2
173	Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. <i>Leukemia and Lymphoma</i> , 2020, 61, 2708-2713.	0.6	2
174	Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-7.	0.6	2
175	The Effect of Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Pre-Post Intervention Pilot Study. <i>Blood</i> , 2015, 126, 4034-4034.	0.6	2
176	Prolonged activated partial thromboplastin time with no clear explanation. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 225-228.	0.5	2
177	Previously undiagnosed cancer in patients with arterial thrombotic events – A population-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 635-647.	1.9	2
178	Translocation t(3;17)(q23;q21): a new translocation in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 00-00.	1.2	1
179	Reply to N. Reddy et al. <i>Journal of Clinical Oncology</i> , 2009, 27, 2297-2298.	0.8	1
180	Introduction. <i>Acta Haematologica</i> , 2011, 125, 5-7.	0.7	1

#	ARTICLE	IF	CITATIONS
181	Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 2939-2945.	0.8	1
182	Kinetics of <sc>preâ€myelodysplastic</sc> syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	0.8	1
183	A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7563-7563.	0.8	1
184	Factors That Dictate Mental Coping Strategies Used By Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 5899-5899.	0.6	1
185	Myeloid Colony-Stimulating Factors Do Not Increase the Risk of Mortality or Disease Activity Measures in Patients with Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.. <i>Blood</i> , 2009, 114, 2045-2045.	0.6	1
186	Anthracycline-Containing Regimens for Treatment of Follicular Lymphoma In Adults: Systematic Review and Meta-Analysis.. <i>Blood</i> , 2010, 116, 2820-2820.	0.6	1
187	Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials. <i>Blood</i> , 2011, 118, 2591-2591.	0.6	1
188	Autoimmune and Inflammatory Manifestations Associated with Acute Myeloid Leukemia with Trisomy 8 â€“ Case Series and Review of the Literature.. <i>European Journal of Haematology</i> , 2021, , .	1.1	1
189	CLL-Derived Exosomes Turn Endothelial Cells into IL-6 Producing Cells. <i>Blood</i> , 2021, 138, 1547-1547.	0.6	1
190	Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 4876-4876.	0.6	1
191	Thalassemia Major and Intermedia in Patients Older than 35 Years: A Single Center Experience. <i>Israel Medical Association Journal</i> , 2017, 19, 767-771.	0.1	1
192	Cancerâ€associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	1.0	1
193	Taming of the Shrew - Overcoming Extramedullary Blast Crisis in the Era of the New Tyrosine Kinase Inhibitors. <i>Acta Haematologica</i> , 2013, 130, 108-110.	0.7	0
194	The Challenges and Perspectives in Treating Adolescent and Young Adult Patients with Hematological Malignancies. <i>Acta Haematologica</i> , 2014, 132, 263-263.	0.7	0
195	The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective. <i>Acta Haematologica</i> , 2016, 135, 131-132.	0.7	0
196	Reply: Letter to the Editor Regarding â€Autologous Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysisâ€; <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e114-e115.	2.0	0
197	Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease. <i>Acta Haematologica</i> , 2021, 144, 229-235.	0.7	0
198	From the Editorâ€™s Desk: Publishing in Times of a Pandemic. <i>Acta Haematologica</i> , 2021, 144, 473-475.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Cardiology</i> , 2021, 146, 1-6.	0.6	0
200	Right Coronary Artery "Vessel Floating Sign" in a Patient With Primary Cardiac Lymphoma. <i>JACC: Case Reports</i> , 2021, 3, 1524-1526.	0.3	0
201	A Pilot Study of Combined Escalated BEACOPP-ABVD Therapy for Advanced Hodgkin's Lymphoma Patients with High IPS Score: The Israel Cooperative Lymphoma Group.. <i>Blood</i> , 2004, 104, 4576-4576.	0.6	0
202	Spontaneous Pregnancy and Fertility Preservation Program in Women Undergoing High Dose Chemotherapy for Hematological Malignancies.. <i>Blood</i> , 2005, 106, 1114-1114.	0.6	0
203	ATG Plus Cyclosporine-a Should Be Used as Immunosuppressive Therapy in Patients with Severe Aplastic Anemia-Systematic Review and Meta-Analysis. <i>Blood</i> , 2008, 112, 4120-4120.	0.6	0
204	Hematopoietic Growth Factors In Aplastic Anemia Patients Treated with Immunosuppressive Therapy: Systematic Review and Meta-Analysis - 2010 Update.. <i>Blood</i> , 2010, 116, 1164-1164.	0.6	0
205	Increased Activity of Prothrombinase Fgl-2 in Peripheral Blood Mononuclear Cells of Patients with B-Cell Lymphoma.. <i>Blood</i> , 2012, 120, 2665-2665.	0.6	0
206	The Role of Anti-CD33 for the Treatment of Acute Myeloid Leukemia " Systematic Review and Meta-Analysis. <i>Blood</i> , 2012, 120, 1521-1521.	0.6	0
207	Enhanced Adhesion, Migration and Pyk2 Expression in K562 Cells Following Imatinib Treatment. <i>Blood</i> , 2012, 120, 4426-4426.	0.6	0
208	CHOP/CHOP-Like-14 Vs. CHOP/CHOP-Like-21 For Patients With Aggressive Lymphoma " a Systematic Review and Meta-Analysis Of Randomized Controlled Trials. <i>Blood</i> , 2013, 122, 1798-1798.	0.6	0
209	Continuous Platelet Transfusion Increases Platelet Increment in Refractory Hemato-Oncological Patients " a Single Center Experience. <i>Blood</i> , 2014, 124, 2888-2888.	0.6	0
210	The Role of the Newer Tyrosine Kinase Inhibitors As First Line Treatment in Chronic Phase Chronic Myeloid Leukemia " an Updated Meta-Analysis. <i>Blood</i> , 2014, 124, 4563-4563.	0.6	0
211	Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis. <i>Blood</i> , 2014, 124, 5567-5567.	0.6	0
212	Muscle Mass in Elderly Patients with DLBCL Treated with RCHOP. <i>Blood</i> , 2016, 128, 3044-3044.	0.6	0
213	Risk Factors for Early Mortality in Hemato-Oncological Patients with Carbapenem Resistant <i>Acinetobacter Baumannii</i> (CRAB) Bacteremia. <i>Blood</i> , 2018, 132, 4953-4953.	0.6	0
214	Sequential Treatment with FLAG-IDA Salvage Chemotherapy Followed By Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia. <i>Blood</i> , 2018, 132, 5788-5788.	0.6	0
215	The Yield and Safety of Skin Biopsies in Acute Myeloid Leukemia Patients during Intensive Chemotherapy Treatment. <i>Blood</i> , 2019, 134, 5110-5110.	0.6	0
216	Reduced Number and Function of Endothelial Progenitor Cells in Patients with Beta Thalassemia Major. <i>Blood</i> , 2019, 134, 2247-2247.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study. <i>Blood</i> , 2019, 134, 5703-5703.	0.6	0
218	WhatsApp in Acta Haematologica?. <i>Acta Haematologica</i> , 2020, 143, 190-190.	0.7	0
219	Between a Rock and a Hard Place: Paraproteinemia Associated with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1488-1488.	0.6	0
220	Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 4364-4364.	0.6	0
221	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study. <i>Blood</i> , 2021, 138, 3962-3962.	0.6	0
222	Risk Assessment and Management of Venous Thromboembolism in Cancer Patients: A Population-Based Cohort Study. <i>Blood</i> , 2020, 136, 27-27.	0.6	0
223	Diarrheal Morbidity in Patients Undergoing Hematopoietic Cell Transplantation - the Diagnostic Yield of Stool Cultures. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
224	A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
225	Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study. <i>Leukemia and Lymphoma</i> , 0, , 1-8.	0.6	0
226	The utility of the novel optimized HLH inflammatory (OHI) index for predicting the risk for mortality and causes of death in lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7570-7570.	0.8	0